SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Check Before You Invest : Kilitch Drugs (India) Ltd

BSE: 524500 NSE: KILITCH ISIN: INE729D01010
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Kilitch Drugs (India) Ltd belong to?
Kilitch Drugs (India) Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Kilitch Drugs (India) Ltd a good quality company?
Kilitch Drugs (India) Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Kilitch Drugs (India) Ltd undervalued or overvalued?
Kilitch Drugs (India) Ltd appears Fair, as its key valuation ratios are in line with their past averages.
Q.4 Is Kilitch Drugs (India) Ltd a good buy now?
Kilitch Drugs (India) Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd revenue growth is 38% for FY-2025 , which is above its 5 year CAGR of 24.5% , indicating faster growth.
Q.2 Gross Profit margin of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Gross profit margin which is the profit after deduction of direct costs, is 23.4% for FY-2025 , which is above its 5 year median of 17.7% , indicating increasing margins.
Q.3 Operating Profit Margin of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 17.14% for FY-2025 , which is above its 5 year median of 14.72% indicating increasing margins.
Q.4 Net Profit Margin of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Net Profit Margin is 17.16% for FY-2025 , is above with its 5 year median of 13.34%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 23.4 17.7
Operating Profit Margin 17.14 14.72
Net Profit Margin 17.16 13.34
Q.5 Return on Asset of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Return on Asset is 9.73%, which is above its 5 year historical median of 6.53%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Return on equity is 13.11% for FY-2025 , which is above its historical median of 8.51%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Return on capital employed is 15.49% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Cash conversion cycle is 58 days, above its historical median of 55 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.57 0.49
ROE 13.11 8.51
ROCE 15.49 9.9
Cash Conversion Cycle 58 days 55 days
Q.9 Debt to Equity ratio of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Debt-to-Equity ratio is 0.19 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd Debt to cash flow from operations is 3.22 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Kilitch Drugs (India) Ltd?
Promoters hold 63.77% of the Kilitch Drugs (India) Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Kilitch Drugs (India) Ltd vs industry peers?
Kilitch Drugs (India) Ltd revenue CAGR is 24.47% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 181.6 137.1
Gross Profit 42.6 15.1
Operating Profit 31 16
Net Profit 31 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.57 0.8
ROE 13.11 8.91
ROCE 15.49 11.59
Cash Conversion Cycle (days) 57.86 76

Valuation & price assessment

Q.1 Stock return of Kilitch Drugs (India) Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 21.9% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 21.9% 21.8% 18.4% -20.7%
Q.3 Valuation ratios of Kilitch Drugs (India) Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 15.33 0.00 40.28
Price to Book 1.35 0.92 2.77
Price to Sales 2.64 2.32 2.65
EV to EBITDA 12.11 25.97 15.67

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×